Skip to main content

Marker Therapeutics, Inc 8-K, filed Nov 19, 2026

Marker Therapeutics, Inc. (MRKR)

8-K 2026-11-19 For: 2026-11-19
View Original
Added on November 19, 2026

About this 8-K

Marker Therapeutics, Inc filed this 8-K on November 19, 2026.

Marker Therapeutics was awarded a $16.2 million Product Development Research grant from the Cancer Prevention and Research Institute of Texas to support its lead MAR-T therapy, MT-601, in the planned Phase 2 APOLLO study. AI summary

Items reported

  • Item 8.01: Other events
  • Item 9.01: Financial statements and exhibits